- Home
- AMSF vs LENZ Comparison
AMSF vs LENZ Comparison
Compare AMSF & LENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMSF
- LENZ
- Stock Information
- Founded
- AMSF 1985
- LENZ 2019
- Country
- AMSF United States
- LENZ United States
- Employees
- AMSF N/A
- LENZ N/A
- Industry
- AMSF Accident &Health Insurance
- LENZ Medicinal Chemicals and Botanical Products
- Sector
- AMSF Finance
- LENZ Health Care
- Exchange
- AMSF Nasdaq
- LENZ Nasdaq
- Market Cap
- AMSF 869.6M
- LENZ 819.1M
- IPO Year
- AMSF 2005
- LENZ 2021
- Fundamental
- Price
- AMSF $43.50
- LENZ $29.94
- Analyst Decision
- AMSF Buy
- LENZ Strong Buy
- Analyst Count
- AMSF 2
- LENZ 5
- Target Price
- AMSF $59.50
- LENZ $41.80
- AVG Volume (30 Days)
- AMSF 130.4K
- LENZ 274.7K
- Earning Date
- AMSF 07-28-2025
- LENZ 05-07-2025
- Dividend Yield
- AMSF 10.39%
- LENZ N/A
- EPS Growth
- AMSF N/A
- LENZ N/A
- EPS
- AMSF 2.48
- LENZ N/A
- Revenue
- AMSF $301,216,000.00
- LENZ N/A
- Revenue This Year
- AMSF $1.69
- LENZ N/A
- Revenue Next Year
- AMSF $6.54
- LENZ $544.79
- P/E Ratio
- AMSF $17.54
- LENZ N/A
- Revenue Growth
- AMSF N/A
- LENZ N/A
- 52 Week Low
- AMSF $42.26
- LENZ $16.28
- 52 Week High
- AMSF $60.24
- LENZ $38.93
- Technical
- Relative Strength Index (RSI)
- AMSF 29.18
- LENZ 54.67
- Support Level
- AMSF $44.64
- LENZ $27.91
- Resistance Level
- AMSF $44.94
- LENZ $30.76
- Average True Range (ATR)
- AMSF 0.85
- LENZ 2.09
- MACD
- AMSF -0.19
- LENZ -0.14
- Stochastic Oscillator
- AMSF 2.27
- LENZ 38.41
About AMSF AMERISAFE Inc.
AMERISAFE Inc is a specialty provider of workers' compensation insurance focused on small to mid-sized employers engaged in hazardous industries, principally construction, trucking, logging and lumber, agriculture, manufacturing, maritime, and telecommunications. The company generates a majority of its revenue in the form of premiums.
About LENZ LENZ Therapeutics Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.